COMBINATION ANTIHYPERTENSIVE THERAPY FOR MILD-TO-MODERATE ARTERIAL HYPERTENSION AND CONCOMITANT CORONARY HEART DISEASE
- Authors: Cheremushkin S.1, Kucheryavyi Y.1, Oganesyan T.1
-
Affiliations:
- N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
- Issue: Vol 23, No 3 (2012)
- Pages: 76
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115379
- ID: 115379
Cite item
Open Access
Access granted
Abstract
The paper considers problems in the correction of arterial hypertension (AH) with nebivolol in patients with concomitant coronary heart disease (CHD). It gives the data of a prospective comparative study of the efficiency and safety (evaluation of clinical equivalence) of 2 combination therapy regimens using the generic Nebivator (INN Nebivolol; АТС code C07AB12) and the original drug Nebilet in patients with mild-to-moderate AH with concomitant CHD.
Full Text
About the authors
S. Cheremushkin
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
Email: svch555362@yandex.ru
Yu. Kucheryavyi
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
T. Oganesyan
N.A. Semashko Central Clinical Hospital Two, ОАО “RZhD”
References
- Devereaux P., Scott Beattie W., Choi P. et al. How strong is the evidence for the use of perioperative b-blockers in non-cardiac surgery? Systematic review and metaanalysis of randomised controlled trials // BMJ. - 2005; 331: 313-321.
- Рылова A.K., Розанов A.B. Терапия бета-блокаторами в специальных группах пациентов, страдающих ХСН (обзор результатов анализа в подгруппах исследований CIBIS. //, COMET., Copernicus и MERIT HF) // Сердце. - 2003; 2: 193-196.
- Flather M., Shibata М., Coats A. et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) // Eur. Heart J. - 2005; 26: 215-225.
- Маколкин В.И. Роль бета-блокаторов в лечении стабильной стенокардии // Трудный пациент, - 2006; 1: 5-10.
- Маколкин В.И. Позиция β-адреноблокаторов и диуретиков в обновленных Европейских рекомендациях по артериальной гипертензии (2009) // Лечащий врач. - 2010; 7: 35-39.
- Маколкин В.И. Выбор бета-блокаторов при артериальной гипертонии в сочетании с сахарным диабетом: принцип разумной целесообразности // Мат. научно-практической конф. «Метаболические аспекты артериальной гипертонии». Москва, 5 декабря 2002 г.
- Le Brocq М., Leslie S., Milliken P. et al. Endothelial dysfunction: from molecular mechanism stomeasurement, clinical implications, and therapeutic opportunities // Antioxid. Redox Signal. - 2008; 10: 1631-1674.
- Pedersen M., Cockcroft J. The vasodilatory beta-blockers // Curr. Hypertens. Rep. - 2007; 9: 269-277.
- Arosio E., De Marchi S., Prior M. et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress // J. Hypertens. - 2002; 20: 1793-1797.
- Eagle K., Berger P., Calkins H. et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery-executive summary // J. Am. Coll. Cardiol. - 2002; 39: 542-553.
- Cleophas T., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients // Am. J. Ther. 2006; 13: 192-197.
- Cleophas T., Agrawal R., Lichtenthal A. et al. Nationwide efficacy-safety study of nebivolol in mildly hypertensive patients // Am. J. Ther. - 2006; 13: 192-197.
- Van Bortel L., Fici F., Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis // Am. J. Cardiovasc - Drugs. - 2008; 8: 35-44.
- Смирнова O.B. Сравнительная фармакотерапевтическая эффективность β-блокаторов различных групп (пропранолол, атенолол, небиволол) при хронической сердечной недостаточности в эксперименте и клинике: дисс.. канд. мед. наук, -ЯГМА., 2002. - С. 117.
- Dahlof В., Lindholm L. et al. Morbidity and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertension) // Lancet. - 1991; 338: 1281-1285.
- Medical Research Council Working Party. MRC Trial of treatment of mild hyperten-sion // BMJ. - 1985; 291: 47-104.
- The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and LipidLowering treatment to prevent Heart Attack Trial (ALLHAT) // JAMA. - 2002; 288: 2988-2997.
Supplementary files
